Gemcitabine-Induced Hemolytic Uremic Syndrome in Pancreatic Cancer: A Case Report and Review of the Literature
Gut and Liver
;
: 109-112, 2014.
Article
in English
| WPRIM
| ID: wpr-36645
ABSTRACT
Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, and the disease has a high mortality rate. This study reports a case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pancreatic Neoplasms
/
Treatment Outcome
/
Deoxycytidine
/
Hemolytic-Uremic Syndrome
/
Antimetabolites, Antineoplastic
Limits:
Humans
/
Male
Language:
English
Journal:
Gut and Liver
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS